287 related articles for article (PubMed ID: 17428320)
1. Identification of women with an increased risk of developing radiation-induced breast cancer: a case only study.
Broeks A; Braaf LM; Huseinovic A; Nooijen A; Urbanus J; Hogervorst FB; Schmidt MK; Klijn JG; Russell NS; Van Leeuwen FE; Van 't Veer LJ
Breast Cancer Res; 2007; 9(2):R26. PubMed ID: 17428320
[TBL] [Abstract][Full Text] [Related]
2. Contralateral Breast Cancer Risk Among Carriers of Germline Pathogenic Variants in
Yadav S; Boddicker NJ; Na J; Polley EC; Hu C; Hart SN; Gnanaolivu RD; Larson N; Holtegaard S; Huang H; Dunn CA; Teras LR; Patel AV; Lacey JV; Neuhausen SL; Martinez E; Haiman C; Chen F; Ruddy KJ; Olson JE; John EM; Kurian AW; Sandler DP; O'Brien KM; Taylor JA; Weinberg CR; Anton-Culver H; Ziogas A; Zirpoli G; Goldgar DE; Palmer JR; Domchek SM; Weitzel JN; Nathanson KL; Kraft P; Couch FJ
J Clin Oncol; 2023 Mar; 41(9):1703-1713. PubMed ID: 36623243
[TBL] [Abstract][Full Text] [Related]
3. The spectrum of ATM missense variants and their contribution to contralateral breast cancer.
Broeks A; Braaf LM; Huseinovic A; Schmidt MK; Russell NS; van Leeuwen FE; Hogervorst FB; Van 't Veer LJ
Breast Cancer Res Treat; 2008 Jan; 107(2):243-8. PubMed ID: 17393301
[TBL] [Abstract][Full Text] [Related]
4. Radiation Treatment, ATM, BRCA1/2, and CHEK2*1100delC Pathogenic Variants and Risk of Contralateral Breast Cancer.
Reiner AS; Robson ME; Mellemkjær L; Tischkowitz M; John EM; Lynch CF; Brooks JD; Boice JD; Knight JA; Teraoka SN; Liang X; Woods M; Shen R; Shore RE; Stram DO; Thomas DC; Malone KE; Bernstein L; Riaz N; Woodward W; Powell S; Goldgar D; Concannon P; ; Bernstein JL
J Natl Cancer Inst; 2020 Dec; 112(12):1275-1279. PubMed ID: 32119081
[TBL] [Abstract][Full Text] [Related]
5. Study design: evaluating gene-environment interactions in the etiology of breast cancer - the WECARE study.
Bernstein JL; Langholz B; Haile RW; Bernstein L; Thomas DC; Stovall M; Malone KE; Lynch CF; Olsen JH; Anton-Culver H; Shore RE; Boice JD; Berkowitz GS; Gatti RA; Teitelbaum SL; Smith SA; Rosenstein BS; Børresen-Dale AL; Concannon P; Thompson WD;
Breast Cancer Res; 2004; 6(3):R199-214. PubMed ID: 15084244
[TBL] [Abstract][Full Text] [Related]
6. [The clinical importance of a genetic analysis of moderate-risk cancer susceptibility genes in breast and other cancer patients from the Czech Republic].
Pohlreich P; Kleibl Z; Kleiblová P; Janatová M; Soukupová J; Macháčková E; Házová J; Vašíčková P; Sťahlová Hrabincová E; Navrátilová M; Svoboda M; Foretová L
Klin Onkol; 2012; 25 Suppl():S59-66. PubMed ID: 22920209
[TBL] [Abstract][Full Text] [Related]
7. Histopathological features of breast cancer in carriers of ATM gene variants.
Balleine RL; Murali R; Bilous AM; Farshid G; Waring P; Provan P; Byth K; Thorne H; ; Kirk JA
Histopathology; 2006 Nov; 49(5):523-32. PubMed ID: 17064299
[TBL] [Abstract][Full Text] [Related]
8. ATM germline mutations in Spanish early-onset breast cancer patients negative for BRCA1/BRCA2 mutations.
Brunet J; Gutiérrez-Enríquez S; Torres A; Bérez V; Sanjosé S; Galceran J; Izquierdo A; Menéndez JA; Gumà J; Borràs J
Clin Genet; 2008 May; 73(5):465-73. PubMed ID: 18384426
[TBL] [Abstract][Full Text] [Related]
9. Radiation clastogenesis and cell cycle checkpoint function as functional markers of breast cancer risk.
Kaufmann WK; Filatov L; Oglesbee SE; Simpson DA; Lotano MA; McKeen HD; Sawyer LR; Moore DT; Millikan RC; Cordeiro-Stone M; Carey LA
Carcinogenesis; 2006 Dec; 27(12):2519-27. PubMed ID: 16777992
[TBL] [Abstract][Full Text] [Related]
10. Contralateral breast cancer after radiotherapy among BRCA1 and BRCA2 mutation carriers: a WECARE study report.
Bernstein JL; Thomas DC; Shore RE; Robson M; Boice JD; Stovall M; Andersson M; Bernstein L; Malone KE; Reiner AS; Lynch CF; Capanu M; Smith SA; Tellhed L; Teraoka SN; Begg CB; Olsen JH; Mellemkjaer L; Liang X; Diep AT; Borg A; Concannon P; Haile RW;
Eur J Cancer; 2013 Sep; 49(14):2979-85. PubMed ID: 23706288
[TBL] [Abstract][Full Text] [Related]
11. Radiation exposure, the ATM Gene, and contralateral breast cancer in the women's environmental cancer and radiation epidemiology study.
Bernstein JL; Haile RW; Stovall M; Boice JD; Shore RE; Langholz B; Thomas DC; Bernstein L; Lynch CF; Olsen JH; Malone KE; Mellemkjaer L; Borresen-Dale AL; Rosenstein BS; Teraoka SN; Diep AT; Smith SA; Capanu M; Reiner AS; Liang X; Gatti RA; Concannon P;
J Natl Cancer Inst; 2010 Apr; 102(7):475-83. PubMed ID: 20305132
[TBL] [Abstract][Full Text] [Related]
12. Associations Between Cancer Predisposition Testing Panel Genes and Breast Cancer.
Couch FJ; Shimelis H; Hu C; Hart SN; Polley EC; Na J; Hallberg E; Moore R; Thomas A; Lilyquist J; Feng B; McFarland R; Pesaran T; Huether R; LaDuca H; Chao EC; Goldgar DE; Dolinsky JS
JAMA Oncol; 2017 Sep; 3(9):1190-1196. PubMed ID: 28418444
[TBL] [Abstract][Full Text] [Related]
13. Gene-gene interactions in breast cancer susceptibility.
Turnbull C; Seal S; Renwick A; Warren-Perry M; Hughes D; Elliott A; Pernet D; Peock S; Adlard JW; Barwell J; Berg J; Brady AF; Brewer C; Brice G; Chapman C; Cook J; Davidson R; Donaldson A; Douglas F; Greenhalgh L; Henderson A; Izatt L; Kumar A; Lalloo F; Miedzybrodzka Z; Morrison PJ; Paterson J; Porteous M; Rogers MT; Shanley S; Walker L; ; Ahmed M; Eccles D; Evans DG; Donnelly P; Easton DF; Stratton MR; Rahman N
Hum Mol Genet; 2012 Feb; 21(4):958-62. PubMed ID: 22072393
[TBL] [Abstract][Full Text] [Related]
14. ATM germline mutations in women with familial breast cancer and a relative with haematological malignancy.
Paglia LL; Laugé A; Weber J; Champ J; Cavaciuti E; Russo A; Viovy JL; Stoppa-Lyonnet D
Breast Cancer Res Treat; 2010 Jan; 119(2):443-52. PubMed ID: 19404735
[TBL] [Abstract][Full Text] [Related]
15. The genetic epidemiology of breast cancer genes.
Thompson D; Easton D
J Mammary Gland Biol Neoplasia; 2004 Jul; 9(3):221-36. PubMed ID: 15557796
[TBL] [Abstract][Full Text] [Related]
16. Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer.
Walsh T; Casadei S; Coats KH; Swisher E; Stray SM; Higgins J; Roach KC; Mandell J; Lee MK; Ciernikova S; Foretova L; Soucek P; King MC
JAMA; 2006 Mar; 295(12):1379-88. PubMed ID: 16551709
[TBL] [Abstract][Full Text] [Related]
17. Risk for contralateral breast cancer among carriers of the CHEK2*1100delC mutation in the WECARE Study.
Mellemkjaer L; Dahl C; Olsen JH; Bertelsen L; Guldberg P; Christensen J; Børresen-Dale AL; Stovall M; Langholz B; Bernstein L; Lynch CF; Malone KE; Haile RW; Andersson M; Thomas DC; Concannon P; Capanu M; Boice JD; ; Bernstein JL
Br J Cancer; 2008 Feb; 98(4):728-33. PubMed ID: 18253122
[TBL] [Abstract][Full Text] [Related]
18. Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals.
Kuusisto KM; Bebel A; Vihinen M; Schleutker J; Sallinen SL
Breast Cancer Res; 2011 Feb; 13(1):R20. PubMed ID: 21356067
[TBL] [Abstract][Full Text] [Related]
19. Promoter methylation patterns of ATM, ATR, BRCA1, BRCA2 and p53 as putative cancer risk modifiers in Jewish BRCA1/BRCA2 mutation carriers.
Kontorovich T; Cohen Y; Nir U; Friedman E
Breast Cancer Res Treat; 2009 Jul; 116(1):195-200. PubMed ID: 18642075
[TBL] [Abstract][Full Text] [Related]
20. Germline testing of
Woodward ER; Lalloo F; Forde C; Pugh S; Burghel GJ; Schlecht H; Harkness EF; Howell A; Howell SJ; Gandhi A; Evans DG
J Med Genet; 2024 Mar; 61(4):385-391. PubMed ID: 38123987
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
